Immune checkpoint inhibitors promote endothelial inflammatory responses

Clicks: 1
ID: 323326
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #199 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy, yet their efficacy can be compromised by immune-related adverse events (irAEs). Although initially, research focused on myocarditis, more recent data suggest an increased incidence of vascular events, such as myocardial infarction, after initiation of ICI-treatment. With the expanding indications (and duration) of ICI treatment, cardiovascular safety gains importance even more. Purpose This study explored a possible relationship between ICI treatment and acute endothelial inflammation and activation, using a combination of in vivo mouse models and in vitro human and murine cellular assays. Methods ICI were evaluated in 3 different models: 1. C57BL/6J mice; 2. Hyperlipidaemic ApoE-/- mice; 3. C57BL/6J pretreated with doxorubicin (DOX, for 3 weeks, 4 mg/kg/week) to induce an inflammatory phenotype. Mice received three doses of anti-CTLA-4 and anti-PD-1 (7 mg/kg, each, i.p.) as combination over one week or Vehicle injections. Afterwards, vascular reactivity of the thoracic aorta was analysed ex vivo and molecular analyses were conducted. Additionally, primary murine cardiac microvascular endothelial cells (EC) were treated with either one or both ICI, and with or without DOX. Finally, functional in vitro experiments were conducted with primary human umbilical vein EC (HUVEC) treated with anti-CTLA-4. Results ICI did not alter phenylephrine-induced contraction, nor affected acetylcholine-induced relaxation. However, administration of ICI in vivo led to increased mRNA expression of adhesion molecules (VCAM-1, ICAM-1) and elevated TNF-α in the aorta, suggestive of endothelial inflammation and activation. Notably, mice pretreated with DOX showed an overall increased inflammatory response, which was enhanced after ICI treatment. Interestingly, Serpina3n expression was higher than ICAM-1, VCAM-1, and TNF-α after ICI treatment in mice. Primary murine EC exhibited a 4-fold increase in Vcam-1 and Icam-1 expression in response to DOX alone and DOX combined with ICI. In HUVECs, anti-CTLA-4 treatment increased cell migration and angiogenesis, indicative of an activated phenotype (Figure 1), with upregulation of TNF-α, IL-6 and VCAM-1 (Figure 2). Conclusion Our results indicate a direct inflammatory activation of EC by ICI. Moreover, the effect of ICI was more pronounced after pretreatment with DOX. Given the increasing use of ICI, particularly in combination with other cancer therapies, further research is essential to ensure cardiovascular safety.Figure 1. Figure 2.
Reference Key
openalex_W7172350301 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors D N Krueger, M Tangos, G R Y De Meyer, N Hamdani, P J Guns, C F Franssen
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.215
URL
https://doi.org/10.1093/eurheartjsupp/suag097.215
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.